Eli Lilly and Co.’s announcement Wednesday that it plans to slash the list prices of its popular Humalog and Humulin insulin by 70% isn’t likely to free the company from an avalanche of litigation alleging it used its dominant market position to keep insulin prices high.

Among pending cases is re: Insulin Pricing Litigation filed in 2017 against Lilly, Sanofi and Novo Nordisk alleging insulin-makers conspired with pharmacy benefit managers to increase the list price of their insulin products and then set a lower price for certain bulk drug distributors.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]